Clinical Trials Logo

MGMT-Unmethylated Glioblastoma clinical trials

View clinical trials related to MGMT-Unmethylated Glioblastoma.

Filter by:

NCT ID: NCT03250299 Terminated - Glioblastoma Clinical Trials

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Start date: June 7, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly diagnosed glioblastoma. Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with glioblastoma.

NCT ID: NCT03107780 Recruiting - Glioblastoma Clinical Trials

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Start date: July 9, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.